Industry Insights

1. Error Proofing Single-Use Systems: Three Strategies From Med Device 1/4/2022

   Using lessons learned and best practices from the medical device industry, discover demonstrated error-proofing steps to eliminate risk or potential misconnections when designing single-use systems.

2. Managing Process Knowledge Throughout Drug Development And Manufacturing 10/21/2025

   Discover how digitalizing recipe and risk management helps life sciences teams accelerate drug development, streamline technology transfers, and simplify compliance to improve data integrity.

3. Leveraging AI In Drug Discovery To Treat MS & Other Autoimmune Diseases 5/17/2023

   The advancement of artificial intelligence and machine learning algorithms means we can use large pools of genetic data to identify potential risk factors and disease-causing genes for multiple sclerosis and other autoimmune diseases. This author shares a three-pronged approach to analyzing data for AI algorithms, pitfalls to avoid, and AI for silico modeling.

4. The Benefits Of Coatings For Bioproduction: Stem Cells And Coatings 7/19/2024

   Coatings for cell culture surfaces are an important factor in maintaining the health and pluripotent properties of stem cells.

5. mRNA-Lipid Nanoparticles Circumvent Viral Vector Limitations 6/1/2022

   Both physical and chemical nonviral gene delivery systems for ex vivo genetic modification offer advantages over viral vectors, including smaller scale production and the low risk of immunogenicity.

6. Are Electronic Manufacturing Logbooks Better Than Paper? 4/10/2023

   We accept the aid of automated paperless technology in our everyday lives, so why not in life sciences manufacturing? Check out some of the benefits of eLogbook management.

7. Embracing Digital Transformation In Life Science Manufacturing: A Path To Excellence 1/13/2025

   Discover how life science manufacturers are supported in digital transformation, offering solutions for automation, data integration, and compliance to optimize operations.

8. Are We Adequately Assessing U.S. Pharma Supply Chain Risks? 6/26/2020

   There are gaps in our country’s collective knowledge required to determine the severity of the current pandemic’s risk to our supply chain for drugs. Undoubtedly, these gaps will remain, leaving questions that need to be answered and will, hopefully, serve as a road map for legislators and advocates of the industry.

9. Control Strategy Factors For Drug-Device Combination Products

   Building a control strategy comprises understanding the connectivity among materials of composition, components, constituent parts, final drug-device combination product, and critical process parameters.

10. Your 6 Priority Areas For A Successful 2024 11/27/2023

    As we approach the end of 2023, and pharma/biotech companies finesse their road maps for 2024, this article assesses the six priorities vying for attention.